Novartis AG
The use of a H3R inverse agonist for the treatment of excessive daytime sleepiness associated with parkinson's disease (PD)
Last updated:
Abstract:
The invention relates to the use of Compound (I), as defined herein, or pharmaceutically acceptable salt thereof, in the treatment of excessive daytime sleepiness associated with Parkinson's disease.
Status:
Application
Type:
Utility
Filling date:
10 Oct 2019
Issue date:
9 Dec 2021